Nature Medicine, Published online: 12 May 2025; doi:10.1038/s41591-025-03712-9
A promising phase 1 trial with patients with refractory Hodgkin lymphoma underscores the potential value of allogeneic natural killer (NK) cell therapy guided by NK cell-specific engagers.
SoCalTreatmentServices.com Reaffirms Commitment to Comprehensive Addiction &
New Colorado Bill Protects Beavers to Reduce
Renewable energy – powering a safer and
Humann and Texas Athletics Bring Heart Health
Sorry, the comment form is closed at this time.
